Last reviewed · How we verify

NCT05765617

Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

Completed Phase 2 Last updated 13 March 2023
What this trial tests

Phase 2 trial testing Calcitriol in COVID-19 in 16 participants. Completed in 30 September 2021.

Timeline
1 July 2021
Primary endpoint
30 September 2021
30 September 2021

Quick facts

Lead sponsorUniversitas Sebelas Maret
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment16
Start date1 July 2021
Primary completion30 September 2021
Estimated completion30 September 2021
Sites1 location across Indonesia

Drugs / interventions tested

Conditions studied

Sponsor

Universitas Sebelas Maret — full company profile →

Who can join

Adults 18 to 60, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Calcitriol

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Universitas Sebelas Maret trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05765617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing